Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Hitting the target in HER2 mutant cancers

Nature Cancer volume 3, pages 785–786 (2022)Cite this article

Subjects

Though HER2 (ERBB2) exon 20 insertion mutations occur in ~2% of non-small-cell lung cancers, molecular targeted therapies for such cancers have been lacking. A study now identifies selective HER2 inhibitors that have marked efficacy against tumors driven by HER2 exon 20 insertions, without inhibiting wild-type EGFR activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: HER2 exon 20 insertion mutations in lung cancer.

References

  1. Moasser, M. M. Oncogene 26, 6469–6487 (2007).

    Article  CAS  Google Scholar 

  2. Owens, M. A., Horten, B. C. & Da Silva, M. M. Clin. Breast Cancer 5, 63–69 (2004).

    Article  CAS  Google Scholar 

  3. Nathanson, D. R. et al. Intl J. Cancer 105, 796–802 (2003).

    Article  CAS  Google Scholar 

  4. Stephens, P. et al. Nature 431, 525–526 (2004).

    Article  CAS  Google Scholar 

  5. Slamon, D. J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  6. De Greve, J. et al. Lung Cancer 76, 123–127 (2012).

    Article  Google Scholar 

  7. Gandhi, L. et al. J. Clin. Oncol. 32, 68–75 (2014).

    Article  CAS  Google Scholar 

  8. Kris, M. G. et al. Ann. Onco.l 26, 1421–1427 (2015).

    Article  CAS  Google Scholar 

  9. Elamin, Y. Y. et al. J. Clin. Oncol. 40, 702–709 (2022).

    Article  CAS  Google Scholar 

  10. Wilding, B. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00XXX-X (2022).

  11. Tsurutani, J. et al. Cancer Discov. 10, 688–701 (2020).

    Article  CAS  Google Scholar 

  12. Verma, S. et al. N. Engl. J. Med. 367, 1783–1791 (2012).

    Article  CAS  Google Scholar 

  13. Li, B. T. et al. N. Engl. J. Med. 386, 241–251 (2022).

    Article  CAS  Google Scholar 

  14. Modi, S. et al. N. Engl. J. Med. 382, 610–621 (2020).

    Article  CAS  Google Scholar 

  15. Shitara, K. et al. N. Engl. J. Med. 382, 2419–2430 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

    Ryohei Katayama

Authors
  1. Ryohei Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryohei Katayama.

Ethics declarations

Competing interests

R. Katayama received research funding from Chugai, Toppan Printing, TAKEDA and Daiichi-Sankyo outside the scope of the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katayama, R. Hitting the target in HER2 mutant cancers. Nat Cancer 3, 785–786 (2022). https://doi.org/10.1038/s43018-022-00386-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00386-x

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer